Nervgen Pharma (NGEN) Other Non-Current Liabilities (2024 - 2026)

Nervgen Pharma (NGEN) has reported Other Non-Current Liabilities for 3 consecutive years, with $49.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $49.6 million in Q2 2026; TTM through Jun 2026 was $49.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.8 million, up 24.7% from the prior year.
• Other Non-Current Liabilities was $49.6 million for Q2 2026 at Nervgen Pharma, up from $6.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $49.6 million in Q2 2026 and troughed at $6.8 million in Q1 2026.
• A 3-year average of $18.9 million and a median of $9.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 27.23% in 2025, down 27.23% in 2025.
• Over 3 years, Other Non-Current Liabilities stood at $8.5 million in 2024, then climbed by 27.23% to $10.8 million in 2025, then soared by 359.18% to $49.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $49.6 million (Q2 2026), $6.8 million (Q1 2026), and $10.8 million (Q4 2025), per Business Quant data.